Baxter International traded at $19.87 this Monday February 2nd, decreasing $0.20 or 1.00 percent since the previous trading session. Looking back, over the last four weeks, Baxter International lost 0.10 percent. Over the last 12 months, its price fell by 37.20 percent. Looking ahead, we forecast Baxter International to be priced at 19.45 by the end of this quarter and at 17.71 in one year, according to Trading Economics global macro models projections and analysts expectations.
Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s products include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery and acute therapies. Its renal care offering includes peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. Its medication delivery offerings include intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices. Its pharmaceuticals offerings include premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. Its clinical nutrition offerings include parenteral nutrition (PN) therapies and related products. Its advanced surgery offerings include biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. It also offers polysaccharide hemostatic system (PerClot) products.